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The hallmark of diabetes is the presence of hyperglycemia. In contrast to acute 
hyperglycemia, chronic hyperglycemia impairs the secretion of insulin and contributes to 
insulin resistance and thereby perpetuates the diabetic disease. These damaging effects have 
been referred to as glucotoxicity, the cellular mechanisms of which are only partly 
understood. Amongst others inflammatory cytokines and oxidative stress seem to play an 
important role.  
The concept of glucotoxicity is very important to understand because immediate treatment 
may reverse the negative effects of glucose and increase the chance of remission. Remission, 
which is defined as normalisation of blood glucose and fructosamine levels and resolution of 
clinical signs and glucosuria without further need of antidiabetic therapy, usually occurs 
within the first 3 months after initiating therapy. Up till now no tests have been established 
suitable to predict remission. Insulin concentrations (baseline levels as well as after IV 
glucagon or IV arginine) are usually low at the time of diagnosis because of the suppressive 
effects of glucose. Therefore, the appropriate approach in each cat with diabetes is to aim for 
optimal metabolic control. Intermediate-acting insulins are insulins of first choice in cats with 
uncomplicated diabetes. A porcine derived lente-type insulin (Caninsulin) is licensed for use 
in cats in many countries and probably the insulin most often used. In some cats duration of 
insulin action is less than 12 hours, an additional issue is that insulin absorption may be 
inconsistent causing erratic blood glucose concentrations. In human diabetics the same 
problem exists, which has led to the recent development of insulin analogs. Insulin glargine 
(Lantus) is currently the most frequently used long-acting insulin analog. In cats the duration 
of action is longer for glargine than for lente-type insulins, however, duration is usually less 
than 24 hours and glycemic control is better when given twice daily instead of once daily. 
Insulin glargine may be a suitable alternative for cats in which duration of action of lente-type 
insulin is too short for metabolic control. It has been postulated that the remission rate is 
higher in cats treated with insulin glargine than with other types of insulin. Although our own 
results also showed an advantage of glargine the number of published cases is still too small 
to allow a definitive conclusion.
 
 
Initial dosage (Caninsulin, Lantus) in cats weighing < 4 kg is 1 U/cat given twice daily, cats 
weighing > 4 kg usually receive 1.5 – 2.0 U/cat twice daily. In cats which have a blood 
glucose concentration < 20 mmol/l at the time of diagnosis, no more than 1 U/cat twice daily 
independent of the body weight is given.  
The cat may be hospitalized for 1 – 2 days until work-up is completed. Blood glucose is 
measured 3 – 4 times throughout the day, insulin dosage should be reduced if hypoglycemia is 
detected (glucose < 5 mmol/l). Initial work-up and initiation of treatment may also be started 
on an outpatient basis.  
The cat is a true carnivore which distinguishes it clearly from the omnivorous dog. The 
natural diet of wild felids such as mice and birds contains less than 10% of carbohydrates on a 
dry matter basis. Using low-carbohydrate-high-protein diet results in better clinical control 
and increased rates of diabetic remission. Time of feeding relative to the insulin 
administration does not seem to play a role; the quality of metabolic control in cats receiving 
their meal together with the insulin injection is not different from cats which are fed 45 
minutes after insulin administration. The feeding schedule should, however, be consistent 
from day to day, either two equal size meals around the time of insulin administration or 
“nibbling” throughout day and night.  
Frequent re-evaluations and amendments of insulin dosage are essential to increase the chance 
of diabetic remission. In our hospital re-evaluations are performed 1, 3, 8, 12 weeks after 
diagnosis and then approximately every 4 months. Re-evaluations include history, physical 
examination including body weight and fructosamin. However, since cats are prone to stress 
hyperglycemia blood glucose concentrations measured in the hospital may not reflect the true 
glycemia situation. We therefore aim to introduce so called home monitoring to cat owners 
and we encourage them to generate a blood glucose curve 1 – 2 times per month, in individual 
cases blood glucose curves may be needed more often. Home monitoring is also very helpful 
with regard to diabetic remission. In most cats remission occurs during the first 3 months of 
therapy, if improvement of glycemic control or diabetic remission happens unnoticed serious 
hypoglycaemia may result. Ideally, fasting blood glucose (before the insulin injection) should 
be between 12-15 mmol/l and the nadir 5-9 mmol/l. Dosage changes are performed with 
increments of 0.5 U/cat BID approximately every 5 – 7 days. With this treatment regimen the 
current remission rate in our hospital is approximately 50%. Interestingly, older cats have a 
greater chance of remission than younger cats.  
In a few studies higher remission rates have been reported. However, in these studies owners 
were directed to measure blood glucose at least 3 times daily and to adapt insulin dosages 
accordingly. Additionally, the protocol used aimed for extremely tight glycemic control 
(blood glucose between 2.8 and 11.1mmol/l) which increases the risk of serious 
hypoglycemia. Under more “normal” field conditions a recent survey among practitioners in 
the US showed that the remission rate was 26%. 
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